Which medications can cause urinary retention?

Medications That Cause Urinary Retention

Antimuscarinic medications used for overactive bladder (including oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, and trospium) are the most commonly implicated drugs causing urinary retention, and clinicians must use them with extreme caution in patients with impaired gastric emptying or a history of urinary retention. 1

High-Risk Medication Classes

Antimuscarinic/Anticholinergic Agents

• Overactive bladder medications (oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, trospium) directly impair detrusor contractility and should not be used in patients with narrow-angle glaucoma unless cleared by ophthalmology, and require extreme caution in those with urinary retention history. 1
• Antipsychotic drugs with anticholinergic activity are associated with urinary retention, with ziprasidone causing retention in approximately 1 in 21 patients. 2, 3
• Antidepressant agents carry significant risk, particularly tricyclic antidepressants like imipramine (17.6% incidence), while selective serotonin reuptake inhibitors show lower rates (0.025%). 2, 3
• Mirtazapine inevitably induces acute urinary retention in older males with benign prostatic hyperplasia and cannot be ignored as a causative agent. 4
• Inhaled anticholinergic drugs (ipratropium, tiotropium) increase urinary retention risk by 40%, with highest risk in recent starters, patients with benign prostatic hyperplasia, and those using nebulizers (OR 2.92). 5

Opioid Analgesics

• All opioid medications can cause urinary retention through multiple mechanisms affecting the micturition pathway. 3
• Morphine, codeine, meperidine, tramadol, and tapentadol should be avoided in patients with renal impairment due to metabolite accumulation that worsens retention risk. 6
• Hydrocodone, oxycodone, and hydromorphone require careful dose reduction and neurologic monitoring as they produce metabolites that can precipitate retention. 6

Alpha-Adrenergic Agonists

• Alpha-adrenoceptor agonists impair bladder neck relaxation and increase outlet resistance, directly causing urinary retention. 3

Calcium Channel Blockers

• Nifedipine, diltiazem, and verapamil cause fluid retention that can mimic or exacerbate urinary retention, particularly in heart failure patients. 7

NSAIDs and COX-2 Inhibitors

• Celecoxib and piroxicam showed statistically significant signals for urinary retention in pharmacovigilance analysis, though this adverse effect is not listed in their product labeling. 8
• All NSAIDs including celecoxib cause fluid retention that can contribute to urinary symptoms. 7

Antiarrhythmic Agents

• Flecainide, propafenone, disopyramide, and calcium channel blockers have negative inotropic effects and can contribute to fluid retention states that worsen urinary function. 7

Miscellaneous Agents

• Benzodiazepines impair detrusor contractility through central nervous system depression. 3
• Detrusor relaxants directly inhibit bladder muscle contraction. 3
• Thiazolidinediones (pioglitazone, rosiglitazone) cause significant fluid retention. 7
• Dapagliflozin (SGLT2 inhibitor) showed a new urinary retention signal requiring further evaluation. 8
• Gabapentin and lithium demonstrated statistically significant urinary retention signals not previously described in their labeling. 8

High-Risk Patient Populations

• Elderly patients face substantially higher risk due to comorbidities like benign prostatic hyperplasia and polypharmacy that reinforces impaired micturition. 3
• Men with benign prostatic hyperplasia using inhaled anticholinergics have a 4.67-fold increased risk of acute urinary retention. 5
• Patients on multiple anticholinergic medications experience additive effects that dramatically increase retention risk. 3

Critical Clinical Pitfalls

• Up to 10% of acute urinary retention episodes may be attributable to concomitant medication use, making drug review essential in all cases. 3
• The median time from drug initiation to urinary retention onset is only 7 days, with highest risk in recent starters. 8
• Nebulized anticholinergic administration carries nearly 3-fold higher retention risk compared to other delivery methods. 5
• Combination therapy with multiple drugs affecting micturition (e.g., antimuscarinic for overactive bladder plus alpha-blocker for benign prostatic hyperplasia) requires close monitoring, though antimuscarinics do not appear to significantly increase retention risk when used appropriately in this context. 9